Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday that it has agreed to sell its US Priority Review Voucher for a total cash consideration of USD160m.

The voucher was awarded in February 2025 following US Food and Drug Administration approval of VIMKUNYA, the company's chikungunya vaccine for individuals aged 12 and older.

Under a licence agreement tied to the 2023 acquisition of the vaccine, the National Institutes of Health will receive 20% of the gross proceeds from the sale of the PRV.

The income will be booked as other operating income, leaving 2025 revenue guidance unchanged. However, EBITDA will see a positive impact, and Bavarian Nordic plans to update its EBITDA margin guidance of 26-30% following the transaction's closing.

The deal is subject to customary closing conditions, including anti-trust review, with completion expected in the third quarter of 2025.